2019 American Transplant Congress
Early Achievement of Sustained Virological Response in Liver Transplant Recipients with Hepatitis C Reduces Risks of End Stage Renal Disease
*Purpose: Chronic kidney disease (CKD) is common after liver transplantation (LT) and result worse morbidity and mortality. Hepatitis C virus (HCV) infection is recognized as…2019 American Transplant Congress
Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…2019 American Transplant Congress
De-Novo Letermovir Resistant Mutations in Cytomegalovirus-Infected Tissues of Solid Organs Transplant Recipients
*Purpose: Letermovir, cytomegalovirus (CMV) DNA-terminase complex (UL51, UL56, and UL89) inhibitor, revealed the efficient prophylactic effect against CMV infection including disease and DNAemia with low-grade…2019 American Transplant Congress
Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients
*Purpose: Letermovir is a new antiviral recently approved for cytomegalovirus (CMV) prophylaxis in CMV-seropositive hematopoietic-cell transplant recipients. Its off-label use in solid organ transplant (SOT)…2019 American Transplant Congress
Low-Dose Valacyclovir Prophylaxis for Cytomegalovirus Infection in Renal Transplant Recipients with Intermediate Risk
*Purpose: According to recent guidelines ganciclovir or valganciclovir chemoprophylaxis is recommended for all kidney transplantation (KT) recipients (except for D-/R- serology) for preventing cytomegalovirus (CMV)…2019 American Transplant Congress
The Natural History and Time to Seroconversion of CMV in the Era of Post-Transplantation Chemoprophylaxis: A Single Center Study
Division of Infectious Diseases, University of Arizona, Tucson, AZ
*Purpose: The current cytomegalovirus (CMV) guidelines in solid organ transplantation recommend chemoprophylaxis (ppx) in post-kidney transplantation recipients. This approach has led to a reduction in…2019 American Transplant Congress
Cidofovir for BK Nephropathy Rescue Treatment: A Single Center Experience
*Purpose: Cidofovir is a potentially nephrotoxic antiviral drug used primarily as a treatment for CMV retinitis however due to its potent antiviral effects has been…2019 American Transplant Congress
Protocol Cidofovir for Refractory Polyomavirus Associated Nephropathy in Kidney Transplant Recipients
University of Maryland Medical Center, Baltimore, MD
*Purpose: Dose-limiting nephrotoxicity has historically precluded the use of cidofovir for polyomavirus associated nephropathy (PVAN). With incidence of BK viremia in kidney transplant recipients increasing…2019 American Transplant Congress
Oral Ribavirin Therapy for Respiratory Syncytial Virus (RSV) in Lung Transplant Recipients: The Impact of Policy Implementation on Cost and Appropriate Use
Henry Ford Hospital, Detroit, MI
*Purpose: RSV is a leading cause of viral infections in lung transplant recipients and is associated with significant morbidity and mortality. While the role of…2019 American Transplant Congress
REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: To mitigate the current organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys…
American Transplant Congress abstracts